No Data
No Data
Sunshine Guojian Pharmaceutical was awarded the A-share ESG Value Award of China Listed Companies English and Chinese by 2024.
Shanghai, July 11, 2024 / PRNewswire / - The 2024 China Capital Market Development Forum and Listing Company Forum, sponsored by China Fund News, was recently held in Shanghai. The forum also announced the winners of the 2024 China Listed Company Yinghua Demonstration Case Awards. Sunshine Guojian Pharmaceutical, a leader in innovative antibody drug development in China, won the A-share ESG Value Award. The China Listed Company Yinghua Demonstration Case Awards, initiated by China Fund News, aims to adhere to the spirit of the new "Nine Articles of the State," evaluate the comprehensive strength and value of the enterprise from a long-term and value investment perspective, and select the institutions that invest in them.
Sunshine Guojian Pharmaceutical (688336.SH) plans to distribute 0.05 yuan per share in 2023, with ex-rights and ex-dividends on June 26th.
Sunshine Guojian Pharmaceutical (688336.SH) announced that it plans to distribute a cash dividend of 0.05 yuan per share for the year 2023.
Sunshine Guojian Pharmaceutical (688336.SH) plans to launch a restricted stock incentive plan in 2024 with a grant price of 12.00 yuan/share.
Sunshine Guojian Pharmaceutical (688336.SH) released its restricted stock incentive plan (draft) for 2024. This incentive plan...
Sunshine Guojian Pharmaceutical (688336.SH): Intends to sign an exclusive license agreement with Shenyang Sunshine.
Sunshine Guojian Pharmaceutical (688336.SH) announced on June 5th that the company plans to sign an exclusive license agreement with Shenyang Sunshine, granting Shenyang Sunshine exclusive rights to the company's 706, 709, HBT-2002, QY-F10, QY-F11, QY-F07, and QY-F02 projects in the licensed area (Greater China) for the research and development, registration, improvement, production, use, sale, and promise to sell licensed products against collaborative targets for all approved indications, as well as use other intellectual property licensed by Sunshine Guojian Pharmaceutical to Shenyang Sunshine.
Here's Why We Think Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investment
BeiGene (688235.SH): Revenue exceeded 5 billion yuan in the first quarter, accelerating differentiated innovation
On May 8, BeiGene (688235)'s US stock performance report for the 2024 Q1 quarter and the A-share performance report were freshly released. Financial reports show that during the reporting period, BeiGene's total revenue reached 5.359 billion yuan, up 74.8% year on year; thanks to the rapid release of the two core self-developed products, the company's global product revenue reached 5.325 billion yuan, up 89.6% year on year and 17.8% month on month, exceeding market expectations. At the same time as revenue increased dramatically, thanks to strict expense management, BeiGene's operating expenses grew slowly. Current sales and management expenses accounted for 8 percent of product revenue compared to the same period last year
No Data